Search

Sjogren's syndrome is an autoimmune disease that commonly presents to the ophthalmologist as a dry eye disease. We report an unusual presentation of a case of Sjogren's syndrome. A 33-year-old man presented with lid swelling, pseudomembraneous conjunctivitis with central corneal epithelial defect and history of limb weakness for past 2 years. There was progressive enlargement of the epithelial defect and conjunctival-scleral necrosis developed during follow-up. Evaluation for underlying connective tissue disorder was positive for SS-B/La antibody and, the rheumatoid factor, anti nuclear antibody, anti neutrophil cytoplasmic antibody titres were negative. Patient was diagnosed as a case of Primary Sjogren's syndrome. Resolution of the conjunctival-scleral necrosis occurred following treatment with combination of cyclosporine and prednisolone. Paramedian tarsorrhaphy was performed to promote healing of the corneal epithelium. The corneal epithelium healed, conjunctival-scleral necrosis resolved completely and the visual acuity improved to 6/36 in the right eye after 3 months of immunosuppressive therapy. The immunosuppressive therapy was discontinued after completion of 6 months of treatment. After 6 months follow-up of stopping immunosuppressive therapy, the ocular and systemic condition is stable.

A 13-year-old boy presented with bilateral retrobulbar neuritis. Three months later he presented with unilateral proptosis and cervical lymphadenopathy. Lymph node biopsy confirmed non-Hodgkin's lymphoma, B-cell type. To the best of our knowledge, this is the first reported case of bilateral retrobulbar neuritis as the presumptive initial presentation of non-Hodgkin's lymphoma.

Purpose This study aimed to report the use of intravitreal bevacizumab as an adjunctive treatment in two cases of advanced Eales’ disease with vitreous haemorrhage and tractional retinal detachment, prior to vitreoretinal surgery. Method In two patients presenting with vitreous haemorrhage, retinal neovascularisation and localised tractional retinal detachment, 1.25 mg of intravitreal bevacizumab was injected prior to vitrectomy, membrane peeling and endolaser photocoagulation of retina. Result Regression of the retinal neovascularisation with resolution of dye leakage on fluoroscein angiography was observed in both cases. Membrane peeling could be performed with minimal bleeding during vitreoretinal surgery in both cases. Conclusion Bevacizumab may be a possible adjunctive treatment to vitreoretinal surgery for the management of Eales’ disease with tractional retinal detachment.